16476804

Source:http://linkedlifedata.com/resource/pubmed/id/16476804

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0034261, umls-concept:C0087111, umls-concept:C2875365
pubmed:issue	4
pubmed:dateCreated	2006-4-11
pubmed:abstractText	Midodrine hydrochloride is the only drug demonstrated in a placebo-controlled treatment trial to improve orthostatic hypotension (OH) but it significantly worsens supine hypertension. By enhancing ganglionic transmission, pyridostigmine bromide can potentially ameliorate OH without worsening supine hypertension.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/M01 RR 00585, http://linkedlifedata.com/resource/pubmed/grant/NS 32352, http://linkedlifedata.com/resource/pubmed/grant/NS 39722, http://linkedlifedata.com/resource/pubmed/grant/NS 43364, http://linkedlifedata.com/resource/pubmed/grant/NS 44233
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372436
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cholinesterase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Midodrine, http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine, http://linkedlifedata.com/resource/pubmed/chemical/Pyridostigmine Bromide, http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0003-9942
pubmed:author	pubmed-author:HinesStacyS, pubmed-author:KleinCaroline MCM, pubmed-author:LowPhillip APA, pubmed-author:O'BrienPeter CPC, pubmed-author:Opfer-GehrkingTonette LTL, pubmed-author:SandroniPaolaP, pubmed-author:SingerWolfgangW, pubmed-author:SlezakJeffreyJ, pubmed-author:SuarezGuillermo AGA
pubmed:issnType	Print
pubmed:volume	63
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	513-8
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:16476804-Adolescent, pubmed-meshheading:16476804-Adult, pubmed-meshheading:16476804-Arteries, pubmed-meshheading:16476804-Autonomic Nervous System Diseases, pubmed-meshheading:16476804-Baroreflex, pubmed-meshheading:16476804-Cholinergic Fibers, pubmed-meshheading:16476804-Cholinesterase Inhibitors, pubmed-meshheading:16476804-Cross-Over Studies, pubmed-meshheading:16476804-Double-Blind Method, pubmed-meshheading:16476804-Female, pubmed-meshheading:16476804-Ganglia, Autonomic, pubmed-meshheading:16476804-Ganglia, Sympathetic, pubmed-meshheading:16476804-Humans, pubmed-meshheading:16476804-Male, pubmed-meshheading:16476804-Midodrine, pubmed-meshheading:16476804-Neural Pathways, pubmed-meshheading:16476804-Norepinephrine, pubmed-meshheading:16476804-Pyridostigmine Bromide, pubmed-meshheading:16476804-Regional Blood Flow, pubmed-meshheading:16476804-Shy-Drager Syndrome, pubmed-meshheading:16476804-Treatment Outcome, pubmed-meshheading:16476804-Vasoconstriction, pubmed-meshheading:16476804-Vasoconstrictor Agents
pubmed:year	2006
pubmed:articleTitle	Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
pubmed:affiliation	Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural